Treatment of Hyperlipidemias in Childhood

  • C. J. Glueck
  • R. W. Fallat
  • R. C. Tsang
  • M. J. Mellies
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 82)


Coronary heart disease risk factors can easily be recognized in school children, and even in infancy1,2. It has been proposed that the primary prevention of atherosclerosis might best begin in childhood, a period during which the actual vascular lesion is probably either absent or reversible2. This report is focused on therapy of hyperlipidemias in childhood, with the recognition that there are several effective approaches to normalization of elevated cholesterol and triglyceride. There is as yet, no prospective, longitudinal evidence that normalization of cholesterol and triglyceride levels in childhood will prevent the development and progression of atherosclerosis.


Nicotinic Acid Familial Hypercholesterolemia Coronary Heart Disease Risk Factor Portacaval Shunt Intake History 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lauer RM, Connor WE, Leaverto PE, et al: Coronary heart disease risk factors in school children. Muscatine study. J Pediatr 86:697–706, 1975.PubMedCrossRefGoogle Scholar
  2. 2.
    Glueck CJ, Fallat RW, Tsang R: Hypercholesterolemia and hypertriglyceridemia in children. A pediatric approach to primary atherosclerosis prevention. Am J Dis Child 128: 569–577, 1974.PubMedGoogle Scholar
  3. 3.
    Glueck CJ, Tsang R, Fallat R, et al: Familial hypertriglyceridemia: studies in 130 children and 45 siblings of 36 index cases. Metabolism 22: 1287–1309, 1973.PubMedCrossRefGoogle Scholar
  4. 4.
    Tsang RC, Glueck CJ, Fallat RW, et al: Neonatal familial hypercholesterolemia. Am J Dis Child 129:#1, 83–91, 1975.Google Scholar
  5. 5.
    Tsang RC, Fallat RW, Glueck CJ: Cholesterol at birth and age 1: Comparison of normal and hypercholesterolemic neonates. Pediatrics 53:458–470, 1974.PubMedGoogle Scholar
  6. 6.
    Glueck CJ, Tsang RC: Pediatric familial type II hyperlipoproteinemia: effects of diet on plasma cholesterol in the first year of life. Amer J Clin Nutr 25:224–230, 1972.PubMedGoogle Scholar
  7. 7.
    Glueck CJ, Fallat R, Tsang R: Pediatric familial type II hyperlipoproteinemia, therapy with diet and cholestyramine resin. Pediatrics 52:669–679, 1973.PubMedGoogle Scholar
  8. 8.
    West RJ, Lloyd JK: Use of cholestyramine in treatment of children with familial hypercholesterolemia. Arch Dis in Childhood 48:#5, 370–374, 1973.CrossRefGoogle Scholar
  9. 9.
    West RJ, Lloyd JK: Effect of cholestyramine on intestinal-absorption. Gut 16:93–98, 1975.PubMedCrossRefGoogle Scholar
  10. 10.
    Glueck CJ, Fallat RW, Mellies M, et al: Pediatric familial type II hyperlipoproteinemia: therapy with diet and Colestipol resin. Pediatrics, in press, 1975.Google Scholar
  11. 11.
    Buchwald H, Moore RB, Varco RL: Ten years clinical experience with partial ileal bypass in management of hyperlipidemias. Ann Surg 180:384–392, 1974.PubMedCrossRefGoogle Scholar
  12. 12.
    Moutafis CD, Myand NB, Mancini M, et al: Cholestyramine and nicotinic acid in the treatment of familial hyperbetalipo-proteinemia in the homozygous form. Atherosclerosis 14: 247–258, 1971.PubMedCrossRefGoogle Scholar
  13. 13.
    Stein EA, Mieny C, Spitz L, et al: Portacaval-shunt in four patient with homozygous hypercholesterolemia. Lancet 1: 832–835, 1975.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • C. J. Glueck
    • 1
  • R. W. Fallat
    • 1
  • R. C. Tsang
    • 1
  • M. J. Mellies
    • 1
  1. 1.General Clinical Research and Lipid Research Centers, and the Fels Division of Pediatric Research and Newborn DivisionUniversity of Cincinnati, College of MedicineCincinnatiUSA

Personalised recommendations